Skip to main content

Accelrys Shares Recover from Early Plunge on Non-Compliance News

NEW YORK, Feb.10 (GenomeWeb News) - Shares of Accelrys plunged 20 percent today after the company said it expected a letter of non-compliance from Nasdaq.


As GenomeWeb reported, Accelrys will delay its third quarter earnings due to ongoing discussions with the SEC regarding the company's financial restatements.


Accelrys shares were trading off $0.27, or 4.29%, at $6.03 in mid-afternoon trade.


The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.